Name | DC-S239 |
---|
Description | DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC50 value of 4.59 μM. DC-S239 also displays selectivity for DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a. DC-S239 has anticancer activity[1]. |
---|---|
Related Catalog | |
Target |
IC50: 4.59 μM (SET7)[1] |
In Vitro | DC-S239 inhibits DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a by less than 45%, while it inhibits SET7 by 90% at concentrations of 100 μM[1]. DC-S239 (0-100 μM, 120 h) can inhibit the proliferation of MCF7, HL60 and MV4-11 cells in a dose-dependent manner but no significant effect on the activity of HCT116 and DHL4 cells[1]. Cell Viability Assay[1] Cell Line: MCF7, HL60, DHL4, MV4-11 and HCT116 cell lines Concentration: 0-100 μM Incubation Time: 120 h Result: Inhibited MCF7 and HL60 with the IC50 values of 10.93 μM and 16.43 μM, respectively. |
References |
Molecular Formula | C15H15N3O5S |
---|---|
Molecular Weight | 349.36 |